Palvella Therapeutics (PVLA) vs. The Competition Financial Survey

Palvella Therapeutics (NASDAQ:PVLA) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Palvella Therapeutics to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-44.44%	-36.75%
Palvella Therapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Volatility and Risk

Palvella Therapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of -1.90, meaning that their average stock price is 290% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Palvella Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1	0	12	2	3.00
Palvella Therapeutics Competitors	9903	15310	45655	1602	2.54

Palvella Therapeutics currently has a consensus target price of $213.85, suggesting a potential upside of 40.25%. As a group, “Biotechnology” companies have a potential upside of 127.14%. Given Palvella Therapeutics’ competitors higher possible upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Palvella Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$41.72 million	-27.72
Palvella Therapeutics Competitors	$713.66 million	$10.27 million	-18.80

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Palvella Therapeutics beats its competitors on 7 of the 13 factors compared.

Palvella Therapeutics Company Profile

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.